News Summary

Vancouver-based biotech startup Reverb Therapeutics has successfully closed a $17 million CAD seed round. The financing was led by Amplitude Ventures and saw participation from the Myeloma Investment Fund, KdT Ventures, Finchley Healthcare Ventures, InBC, and Seido Capital. Founded in 2023 by CEO David de Graaf and chief science officer Surjit Dixit, Reverb aims to harness the immune system to combat cancer and autoimmune diseases using its proprietary platform, Amplify•R. This platform modifies immune system proteins called cytokines to target specific cells, potentially overcoming past challenges in cytokine therapy. The seed funding will propel the development of Reverb’s lead program, AMP01, and other initiatives, moving them towards regulatory approval and human trials.